Senesco Technologies, Inc.

Yeda Research and Develpment & Co. Ltd

Merck Serono S. A.

Leonid Reznikov

Charles A Dinarello

John E Thompson

Catherine Taylor

Benjamin Pomerantz

Menachem Rubinstein

Daniela Novick

Yolande Chvatchko

Soo Hyun Kim

Dominic O Cliche

Soo-Hyun Kim

Boris Schwartsburd

Adrienne Boone

Bruce C Galton

Marianne Hopkins

Giamila Fantuzzi

Alden Harken

The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFkB by inhibiting expression of apoptosis-specific eIF-5A.

Inhibition of apoptosis-specific eIF-5A(eIF-5A1&#x2033;) with antisense oligonucleotides and siRNA as anti-inflammatory therapeutics

The present invention provides a method of treatment or prevention of sepsis and other diseases characteristic to the Systemic Inflammatory Response Syndrome (SIRS), including severe sepsis, septic shock, and sepsis related to cardiac dysfunction.

Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis

The present invention provides methods of identifying an incidence of ischemia in mammalian tissue, particularly mammalian heart tissue. Further, a method of reducing apoptosis in mammalian tissue, preferably heart tissue, is provided. These methods involve measuring and comparing the gene expression levels of both apoptosis-specific eIF-5A and proliferating eIF-5A and correlating an incidence of ischemia when the expression level of apoptosis-specific eIF-5a is higher than proliferating eIF-5A. In the method of reducing apoptosis in mammalian tissue, there is provided an agent that inhibits expression of apoptosis-specific eIF-5A. Preferred agents are antisense oligonucleotides to human apoptosis-specific eIF-5A.

Nucleic acids, polypeptides, and methods for modulating apoptosis

Growing community of inventors

Aurora, CO, United States of America

Leonid Reznikov